| Phase III |
|
Gemzar®
(gemcitabine) |
Lilly |
Chemotherapy drug FDA-approved for use in a variety of cancers; being evaluated in combination with other chemotherapy drugs and tandem transplant |
|
Tanespimycin (KOS-953; 17-AAG; geldanamycin) |
Bristol-Myers Squibb |
Inhibitor of a heat shock protein (HSP90) that promotes myeloma cell growth and survival LEARN MORE |
|
Zolinza® (vorinostat, SAHA [suberoylanilide hydroxamic acid]) |
Merck |
Histone deacetylase (HDAC) inhibitor that has shown activity in relapsed and refractory myeloma LEARN MORE |
| Phase II |
|
Afinitor® (everolimus, RAD001, Certican®) |
Novartis |
mTor inhibitor being evaluated in combination with other agents; known as Certican outside the US, where it is used in preventing transplant rejection |
|
Aflibercept (VEGF Trap) |
Regeneron/sanofi-aventis |
Anti-angiogenic fusion protein that binds VEGF |
|
Aplidin® (plitidepsin) |
PharmaMar, SA |
Marine-derived antitumor agent that induces rapid apoptosisLEARN MORE |
|
Bexxar® (iodine I 131 tositumomab) |
GlaxoSmithKline |
FDA-approved radiolabeled monoclonal antibody directed against CD20, a marker found on B cells and 20% to 25% of myeloma cells |
|
Carfilzomib (PR-171) |
Proteolix |
Proteasome inhibitor being evaluated alone, as part of combination therapy, and as maintenance therapy LEARN MORE |
|
CNTO 328 |
Centocor |
Anti-interleukin-6 monoclonal antibody being evaluated alone and in combination with Velcade LEARN MORE |
|
Denosumab (AMG 162) |
Amgen |
Human monoclonal antibody that targets the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits bone destruction; being tested alone and in combination with Zometa |
|
Nexavar® (sorafenib) |
Bayer/Onxy Pharmaceuticals |
Multi-kinase inhibitor FDA-approved for use in renal cell carcinoma that inhibits cell growth and angiogenesis; being evaluated alone and in combination with other agents |
|
Panobinostat (LBH589) |
Novartisr |
Deacetylase (DAC) inhibitor; being evaluated in combination with other agents LEARN MORE |
|
Palbociclib (PD-0332991) |
Pfizer |
Kinase inhibitor being evaluated in combination with Velcade and dexamethasone |
|
Pomalidomide (CC-4047) |
Celgene Corporation |
Type of IMiD™ (immunomodulatory drug) being evaluated alone and in combination with dexamethasone LEARN MORE |
|
Rituxan® (rituximab) |
Genentech/Biogen Idec |
Monoclonal antibody FDA-approved for use in non-Hodgkin lymphoma that targets the CD20 marker found on B cells and 20% to 35% of myeloma cells |
|
Romidepsin (depsipeptide, FK228, FR901228) |
Gloucester Pharmaceuticals/Janssen-Cilag Ltd. |
Histone deacetylase (HDAC) inhibitor being evaluated in combination with Velcade |
|
Sprycel® (dasatinib) |
Bristol-Myers Squibb |
Kinase inhibitor FDA-approved for use in chronic myelogenous leukemia; being evaluated in combination with Velcade or Revlimid-dex |
|
Torisel™ (temsirolimus, CCI-779) |
Wyeth |
mTOR inhibitor FDA-approved for use in renal cell carcinoma; being evaluated alone and in combination with other agents |
|
Treanda®,(bendamustine hydrochloride; known as Ribomustin® in Germany) |
Cephalon Oncology |
Alkylating agent FDA-approved for use in treating leukemia and approved in Germany for use in myeloma; being evaluated as part of various combination therapies |
|
Trisenox® (arsenic trioxide, ATO) |
Cephalon |
Anticancer drug FDA-approved for use in acute promyelocytic leukemia |
|
Vidaza® (azacitidine) |
Pharmion |
Cytotoxic drug FDA-approved for the treatment of myelodysplastic syndromes (MDS) |
|
Romidepsin
(depsipeptide, FK228, FR901228) |
Gloucester Pharmaceuticals
/Janssen-Cilag Ltd. |
Histone deacetylase (HDAC) inhibitor being evaluated in combination with Velcade-dex |
|
Sutent®
(sunitunib malate, SU11248) |
Pfizer |
Multikinase inhibitor that blocks cancer cell proliferation and angiogenesis; FDA-approved for use in renal cell carcinoma and a type of gastrointestinal cancer |
|
Thymoglobulin®
(rabbit anti-thymocyte globulin (rATG) |
Genzyme |
Agent FDA-approved for use with immunosuppressants in the treatment of acute renal graft rejection; being evaluated in combination with melphalan or Rapamune® (sirolimus) |
|
Treanda®
(bendamustine hydrochloride, SDX-105; known as Ribomustin® in Germany) |
Cephalon Oncology |
Alkylating agent FDA-approved for use in treating chronic lymphocytic leukemia and approved in Germany for use in myeloma; recently evaluated as part of various combination therapies |
|
Trisenox®
(arsenic trioxide, ATO) |
Cephalon |
Anticancer drug FDA-approved for use in acute promyelocytic leukemia |
|
Vidaza®
(azacitidine) |
Pharmion |
Cytotoxic drug FDA-approved for the treatment of myelodysplastic syndromes (MDS) |
|
Zarnestra™
(R115777, tipifarnib,FTI) |
Ortho Biotech Oncology Research & Development |
Farnesyl transferase inhibitor with evidence of target modulation in phase I trials |
| Phase I |
|
Anti-KIR (1-7F9) |
Novo Nordisk |
Monoclonal antibody that activates the body's natural killer cells to kill tumor cells |
|
Elotuzumab (HuLuc63; humanized anti-CS1 monoclonal antibody) |
Facet Biotech/Bristol-Myers Squibb |
Monoclonal antibody that binds to CS1, a cell surface protein that is highly expressed on myeloma cells; being evaluated alone and in combination with Velcade LEARN MORE |
|
GRN163L |
Geron Corp. |
Telomerase inhibitor that has been shown in vitro to induce apoptosis and inhibit myeloma cell growth; being evaluated alone and in combination with Velcade |
|
HCD122 |
Novartis |
Anti-CD40 monoclonal antibody |
|
HuMax-CD38 |
Genmab |
Human monoclonal antibody that targets the CD38 molecule, which is highly expressed on the surface of myeloma cells |
|
IMGN901
(huN901-DM1, BB-10901) |
Immunogen |
Monoclonal antibody directed against the CD56 marker found on myeloma cells coupled with a cancer drug |
|
Milatuzumab
(hLL1, IMMU-110) |
Immunomedics |
Humanized monoclonal antibody directed against the CD74 protein found on B cells and myeloma cells |
|
Oncolytic measles virus
(MV-NIS) |
Mayo Clinic |
Genetically engineered measles virus being administered with or without cyclophosphamide |
|
Salinosporamide A
(NPI-0052) |
Nereus Pharmaceuticals |
Novel marine derived proteasome inhibitor active against myeloma cells that are resistant to Velcade |
|
SGN40 |
Seattle Genetics |
Monoclonal antibody directed against CD40 being evaluated in combination with Revlimid-dex or Velcade |
|
Zemplar™
(paricalcitol) |
Abbott |
Activated vitamin D therapy being evaluated in combination with Zometa |
|
Zevalin®
(yttrium Y 90 ibritumomab tiuxetan) |
Cell Therapeutics, Inc. |
Radiolabeled monoclonal antibody FDA-approved for use in combination with Rituxan (rituximab) for the treatment of B-cell non-Hodgkin's lymphoma; the combination is being evaluated prior to high-dose melphalan and stem cell transplant |
